US 12,454,575 B2
Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies
Daniel J. Sexton, Melrose, MA (US); Christopher TenHoor, Hopkinton, MA (US); and Malini Viswanathan, Acton, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Jul. 6, 2023, as Appl. No. 18/347,626.
Application 16/594,218 is a division of application No. 15/830,998, filed on Dec. 4, 2017, granted, now 10,479,834.
Application 18/347,626 is a continuation of application No. 17/203,816, filed on Mar. 17, 2021, granted, now 11,739,152.
Application 17/203,816 is a continuation of application No. 16/594,218, filed on Oct. 7, 2019, granted, now 11,014,988.
Application 15/830,998 is a continuation of application No. 15/139,784, filed on Apr. 27, 2016, granted, now 9,862,768.
Application 15/139,784 is a continuation of application No. 14/122,880, granted, now 9,359,438, previously published as PCT/US2012/040409, filed on Jun. 1, 2012.
Claims priority of provisional application 61/498,266, filed on Jun. 17, 2011.
Claims priority of provisional application 61/492,617, filed on Jun. 2, 2011.
Prior Publication US 2024/0124593 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61K 49/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/283 (2013.01) [A61K 39/3955 (2013.01); A61K 48/00 (2013.01); A61K 49/0002 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01)] 22 Claims
 
1. A nucleic acid or nucleic acids encoding an antibody, wherein the antibody comprises a heavy chain (HC) that comprises a HC variable region (VH) and a HC constant region (CH), wherein the VH comprises a complementarity determining region (HC CDR) 1, a HC CDR2, and a HC CDR3, wherein the HC CDR3 has the amino acid sequence LAIGDSY (SEQ ID NO: 24), the CH has a deletion at the position corresponding to the C-terminal lysine residue of SEQ ID NO: 17, and the VH comprises an amino acid sequence having at least 95% homology with SEQ ID NO: 9; and
a light chain (LC) that comprises a LC variable region (VL) and a LC constant region (CL), wherein the VL comprises a complementarity determining region (LC CDR) 1, a LC CDR2, and a LC CDR3, wherein the LC CDR3 has the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) and wherein the VL comprises an amino acid sequence having at least 95% homology with SEQ ID NO: 10;
wherein the antibody binds an FcRn.